Adoram was chosen to present to an expert panel comprising various regional stakeholders. Dr. Hesham Hamed, our Chief Scientific Officer, showcased Adoram’s business model and unique approach of utilizing allosteric small molecules to address unmet medical needs. The pitch was evaluated based on criteria including the product/service, business model, market/competition, financials, presentation quality, and the team. Adoram won the RtSS and advanced to the quarterfinals of the global start-up competition.